ADVA-NETWORK-SECURITY
20.3.2024 14:01:29 CET | Business Wire | Press release
Adva Network Security announced today that it is launching a nationally funded project to develop cloud-optimized, secure network access technology. As part of the Important Projects of Common European Interest (IPCEI), a comprehensive funding initiative is underway to create scalable, real-time and open Next-Generation Cloud Infrastructure and Services (IPCEI-CIS) aimed at ensuring digital sovereignty. Among the 19 German companies participating, Adva Network Security is responsible for developing highly secure network access technology featuring an integrated edge cloud and software solution for robust operation. The solution will be an essential component of a European independent cloud platform, enabling the rapid processing of mission-critical and sensitive data at the network edge.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240320831952/en/
Funded by the European Union – NextGenerationEU (Graphic: Business Wire)
“The security of mission-critical networks poses major challenges for operators: Quantum computing threatens to compromise established security mechanisms, while the push for digitization requires fast and trusted data processing at the edge of networks. Our project within IPCEI-CIS addresses both of these problems and offers very simple operation through automation,” said Wolfgang Keil, senior director of cybersecurity project management at Adva Network Security. “Leveraging our experience in quantum security, protected hosting and the operation of high-security networks, we’re developing highly secure access to the European cloud. This includes protected hosting of virtualized network functions at the edge, enabling sensitive data to be processed safely and quickly on-site before being transferred securely to the cloud.”
The TRUsted cloud connectivity for automated Endpoint SECurity (TRUE-SEC) project was launched on January 1, 2024, and will run for three years. It is funded by the Federal Ministry for Economic Affairs and Climate Protection based on a resolution of the German Bundestag and financed by the European Union. Its mission is to create an innovative solution for secure network access. Renowned for its expertise in the high-security network domain, Adva Network Security has been entrusted with developing this critical component for an end-to-end European cloud infrastructure. In collaboration with many project partners, IPCEI-CIS aims to establish a standardized, open and sustainable cloud infrastructure that ensures future-proof security for data services that are compliant with stringent regulatory requirements. The initiative marks a crucial step in advancing autonomous and sovereign cloud technology across Europe.
“Already deployed across numerous high-security networks, our technology safeguards some of the most sensitive and mission-critical data. Yet, new threat scenarios require continuous improvement. Through our participation in the IPCEI-CIS initiative, we’re making an important contribution to the sovereignty of European cloud infrastructure and services,” commented Michael Roth, GM of Adva Network Security. “The funding will enable us to expand our competence center for network security in Berlin. Our growing team of cybersecurity and network specialists is playing a vital role in driving the security – and thereby the acceptance – of cloud services through innovative and technologically sophisticated solutions. We’re proud to be able to make this contribution and honored to help shape Germany’s digital future.”
About Adva Network Security
Adva Network Security has built a fierce reputation for protecting packet optical networks. We pioneered low-latency, multi-layer encryption solutions that are right now safeguarding data in motion for many mission-critical applications. Our ConnectGuard™ security technology is even combating tomorrow’s quantum security threats. Built by the industry’s leading security experts, our German-based organization helps organizations and government agencies security-harden their networks to ensure critical infrastructure is protected against cyber threats. Our development and manufacturing processes, as well as our security solutions, have been approved and certified by leading governmental security agencies. For more information on how we can help you, please visit www.advasecurity.com.
Published by
Adva Network Security GmbH, Berlin, Germany
www.advasecurity.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240320831952/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ Expands ConnectAI Charter Program with Mars Snacking22.10.2026 12:45:00 CEST | Press release
Mars joins a growing group of global companies working with NIQ forward-deployed engineers to bring proprietary consumer and market intelligence into enterprise AI workflows NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced Mars as a new ConnectAI Charter client, expanding the program’s growing roster of global companies working with NIQ to build the intelligence foundation for amplifying enterprise AI workflows. Through the ConnectAI Charter Program, NIQ forward-deployed engineers and data scientists are working with Mars to embed NIQ intelligence in the expansion of AI-enabled workflows across its business. The engagement focuses on connecting NIQ data, models, and business context with Mars’ AI ecosystem to help reduce the distance between data and decision-making. Together, they are tackling use cases like conversational analytics and harmonized product data to lay the foundation for future use cases. “As we expand the use of AI across our business, we
Spotlight Medical Announces Successful Independent Evaluation of Its Digital Slide-Based Test for Assessing Recurrence Risk in Early Breast Cancer22.10.2026 12:18:00 CEST | Press release
An independent, blinded evaluation of 620 patients from the phase III PANTHER trial identified nearly one-quarter as Low Risk despite clinically high-risk breast cancer, with favorable ten-year outcomes. Spotlight Medical, a company developing AI-powered prognostic tests in oncology, today announced results from an independent evaluation of myStage Dx, its CE-IVDR-marked test for assessing recurrence risk in patients with hormone receptor-positive, HER2-negative early breast cancer. The study was conducted by researchers at Karolinska Institutet in Sweden. Independent, Blinded Evaluation Using Phase III Trial Data The study used data from 620 patients enrolled in PANTHER, an international randomized phase III trial comparing dose-dense with standard chemotherapy. myStage Dxpredictions were generated blinded to clinical outcomes. Researchers at Karolinska Institutet linked the predictions to patient outcomes and independently assessed prognostic performance according to a prespecified p
Zoomtopia: Zoom lancerer nye AI-funktioner22.10.2026 12:13:00 CEST | Pressemeddelelse
Zoom vil forkorte vejen fra mødebeslutning til udført arbejde. På konferencen Zoomtopia præsenterer virksomheden Unified Context Layer – et fælles informationslag, der forbinder samtaler, dokumenter og data, så AI kan forstå sammenhængen og hjælpe med de næste skridt. Samtidig lanceres flere nye AI-produkter og -funktioner, der skal gøre det lettere at omsætte diskussioner og beslutninger til handling. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20261021318859/da/ I møder og samtaler træffes vigtige beslutninger, og virksomheder får værdifuld indsigt i deres kunder. En kundedialog kan begynde i et møde, fortsætte i telefonen og derefter gå over i en chat. Når informationen spredes mellem forskellige værktøjer, bliver det svært for både medarbejdere og AI-agenter at få et samlet billede af, hvad der er blevet sagt og besluttet. Resultatet er, at værdifuld tid går med at finde ud af, hvad der er blevet sagt og besluttet, og
TACTICAAI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron22.10.2026 12:01:00 CEST | Press release
Collaboration brings together TACTICAAI’s operational decision-intelligence technology and NVIDIA AI capabilities to advance reasoning, autonomous analysis and video intelligence for real-world deployment TACTICAAI, an operational decision-intelligence company, today announced a collaboration with NVIDIA to advance and scale the deployment of agentic AI capabilities. The companies will work together to integrate and optimize NVIDIA Nemotron models within TACTICAAI’s multi-intelligence platform, with a focus on expanding these capabilities and supporting deployment with major customers internationally. The collaboration was announced at NVIDIA GTC Berlin. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022054475/en/ TACTICA AI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron (Graphic: AETOSWire) The collaboration with NVIDIA builds on the company’s existing technology, integrating selected NVIDIA
BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 522.10.2026 12:01:00 CEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2026 financial results on Thursday, November 5, 2026, before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com.To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
